Caffeine
This article was originally published in The Tan Sheet
Executive Summary
BMS requests feedback meeting with FDA to discuss three new efficacy studies supporting Category I status for caffeine 130 mg as analgesic adjuvant when combined with acetaminophen. In 1995, agency classified stimulant as Category I for use as analgesic adjuvant in combination with aspirin and acetaminophen or with aspirin alone. However, FDA concluded there were "inadequate clinical data" to support Category I status for caffeine/acetaminophen combo. BMS markets Aspirin-Free Excedrin, which contains the two ingredients. Firms hopes to meet with agency after June 4. FDA has yet to respond
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning